Bluebird Bio Inc
![Bluebird Bio Inc](https://api.admiralmarkets.com/trade_icons/bright-128/BLUE.png)
Cerrado
0.52 -7.14
Resumen
Variación precio
24h
Mínimo
0.51
Máximo
0.53
Ingresos | -72M |
---|---|
Ventas | 12M |
BPA | -0.66 |
Margen de beneficio | -578.849 |
EBITDA | -84M |
Recomendaciones | Comprar |
---|---|
Estimación a 12 meses | +686.79 upside |
Próximas Ganancias | 5 nov 2024 |
---|
Capitalización de Mercado | 5.7M 240M |
---|---|
Apertura anterior | 7.66 |
Cierre anterior | 0.52 |
Puntuación técnica
By Trading Central
Confianza
Bearish Evidence
Bluebird Bio Inc Gráfico
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Bluebird Bio Inc Esperado
Precio Objetivo
By TipRanks
686.79% repunte
Estimación a 12 meses
Media 4.17 USD 686.79%
Máximo 6 USD
Mínimo 3 USD
De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Bluebird Bio Inc Dist en los últimos 3 meses.
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
EBITDA
Beneficio operativo
$
Acerca de Bluebird Bio Inc
bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.